Bariatric surgery for GERD (gastro-oesophageal reflux disease, or GORD) is an increasingly important consideration for patients living with obesity and chronic acid reflux. The relationship between excess weight and GORD is well established, with raised intra-abdominal pressure impairing the lower oesophageal sphincter and promoting acid reflux. Whilst weight loss through surgery can improve reflux symptoms, the effect varies significantly depending on the procedure chosen. This article explains how different bariatric operations affect GORD, which procedures are recommended, UK eligibility criteria under NICE guidance, and what patients can expect before and after surgery.

How Bariatric Surgery Can Affect Acid Reflux and GORD

Bariatric surgery can reduce GORD symptoms by lowering intra-abdominal pressure and improving lower oesophageal sphincter function, but the effect is highly procedure-dependent and specialist assessment is essential.

Gastro-oesophageal reflux disease (GORD), referred to as GERD in some international contexts, is a chronic condition in which stomach acid flows back into the oesophagus, causing symptoms such as heartburn, regurgitation, and chest discomfort. The relationship between obesity and GORD is well established — excess abdominal fat increases intra-abdominal pressure, which promotes acid reflux and can impair the function of the lower oesophageal sphincter (LOS), the muscular valve that prevents acid from travelling upwards. Hiatal hernia, which is more common in people living with obesity, is an additional structural factor that can worsen reflux by allowing part of the stomach to move above the diaphragm.

For many patients living with obesity, bariatric surgery is considered not only as a weight-loss intervention but also as a potential means of improving or resolving GORD symptoms. Weight loss itself — regardless of the surgical method — can reduce intra-abdominal pressure and improve LOS function, which may translate into reduced reliance on acid-suppressing medicines such as proton pump inhibitors (PPIs), for example omeprazole or lansoprazole. However, any reduction or discontinuation of PPI therapy should always be guided by a clinician and not undertaken independently.

The effect of bariatric surgery on GORD is highly procedure-dependent. Some operations can significantly reduce reflux by altering the anatomy of the upper gastrointestinal tract, while others may worsen or even precipitate new-onset GORD. Non-acid and bile reflux may also contribute to symptoms in some patients, particularly after certain procedures. Understanding these mechanisms is therefore essential when considering surgery as part of a GORD management strategy, and specialist assessment is critically important.

Which Procedures Are Recommended for Patients with GORD

Roux-en-Y gastric bypass is the preferred procedure for patients with pre-existing GORD, whilst sleeve gastrectomy is generally avoided as it can worsen or trigger new reflux symptoms.

Not all bariatric procedures carry the same implications for GORD, and this distinction is central to surgical planning. The two most commonly performed bariatric operations in the UK are the Roux-en-Y gastric bypass (RYGB) and the sleeve gastrectomy. Their effects on GORD differ substantially.

Roux-en-Y gastric bypass is generally considered the preferred option for patients with pre-existing GORD, including those with Barrett's oesophagus or significant oesophagitis. This is supported by guidance from the British Obesity and Metabolic Surgery Society (BOMSS). The procedure creates a small gastric pouch and reroutes the small intestine, which reduces the volume of acid-producing stomach tissue, diverts bile away from the oesophagus, and lowers intragastric pressure. These combined effects reduce oesophageal acid exposure. Published systematic reviews and meta-analyses suggest that RYGB leads to substantial improvement or resolution of GORD symptoms in the majority of patients, often allowing clinician-supervised reduction or discontinuation of PPI therapy.

Sleeve gastrectomy involves removing approximately 80% of the stomach to create a narrow, tube-shaped remnant. Whilst effective for weight loss, this procedure has been associated with new-onset or worsened GORD in a proportion of patients. The altered anatomy can increase intragastric pressure and impair LOS function, potentially exacerbating reflux. Concurrent assessment and repair of hiatal hernia at the time of sleeve gastrectomy may reduce but does not eliminate this risk. In some patients, refractory reflux after sleeve gastrectomy may ultimately require conversion to RYGB. For these reasons, sleeve gastrectomy is generally not recommended as the first-choice procedure in patients with confirmed GORD, significant oesophagitis, or Barrett's oesophagus.

Adjustable gastric banding is now rarely performed in the UK and is associated with risks of reflux and dysphagia; it has largely fallen out of favour.

Patients with GORD who are considering bariatric surgery should discuss procedure selection in detail with their bariatric multidisciplinary team (MDT), which will take into account the severity of reflux, endoscopic findings, and individual clinical factors.

NICE Guidance on Eligibility and Referral Pathways

NICE guidance CG189 requires a BMI of 40 kg/m² or above, or 35–39.9 kg/m² with significant comorbidities including severe GORD, with referral typically initiated by a GP to a tier 3 weight management service.

In the UK, access to bariatric surgery is governed primarily by NICE guidance (CG189: Obesity: identification, assessment and management), supported by NICE Quality Standard QS127. To be considered for bariatric surgery, patients typically need to meet the following criteria:

• A BMI of 40 kg/m² or above, or

• A BMI of 35–39.9 kg/m² with one or more significant obesity-related comorbidities, such as type 2 diabetes, hypertension, or severe GORD

• A BMI of 30–34.9 kg/m² in adults with recent-onset type 2 diabetes (with lower BMI thresholds applying for people of Asian family origin, in line with NICE guidance on ethnicity-related risk)

• Evidence of engagement with non-surgical weight management programmes

• Confirmation that surgery is appropriate following assessment by a specialist MDT

GORD may be considered within the broader category of significant obesity-related comorbidities when it is severe, refractory to medical treatment, or associated with complications such as Barrett's oesophagus. However, eligibility is assessed on an individual basis, and the presence of GORD alone does not automatically confer eligibility for NHS-funded surgery.

Referral pathways typically begin with the GP, who can refer patients to a tier 3 specialist weight management service. Following assessment — which may include dietary review, psychological evaluation, and investigation of comorbidities — patients may then be referred to a tier 4 bariatric surgical service, as defined by the NHS England Severe and Complex Obesity (Adults) Tier 4 Service Specification. Pre-operative investigations for patients with GORD commonly include upper gastrointestinal endoscopy. Oesophageal manometry and pH or impedance studies are used selectively in cases where the clinical picture warrants further evaluation, rather than as a routine requirement for all patients. Patients are encouraged to discuss their symptoms openly with their GP to ensure that GORD is appropriately documented as part of their referral.

Risks, Benefits, and What to Expect After Surgery

RYGB offers substantial GORD improvement for most patients, but all bariatric procedures carry risks including nutritional deficiencies, anastomotic leak, and the need for lifelong supplementation and monitoring.

Bariatric surgery carries both significant potential benefits and recognised risks, and patients should receive thorough pre-operative counselling as part of the informed consent process.

In terms of GORD-specific outcomes, Roux-en-Y gastric bypass is associated with substantial improvement or resolution of reflux symptoms in the majority of patients, according to published systematic reviews, with many individuals able to reduce or discontinue long-term PPI therapy under medical supervision. Beyond GORD, surgery is associated with meaningful improvements in type 2 diabetes, hypertension, obstructive sleep apnoea, and overall quality of life.

All bariatric procedures carry surgical risks, which include:

• Short-term risks: anastomotic leak, bleeding, infection, venous thromboembolism, and anaesthetic complications

• Long-term risks: nutritional deficiencies (particularly of vitamin B12, iron, calcium, and vitamin D), dumping syndrome, internal hernia (a specific risk after RYGB), gallstone formation, and the potential need for revisional surgery

• Marginal ulcer risk after RYGB: early PPI therapy is typically prescribed post-operatively to reduce this risk; patients should follow their surgical team's advice regarding duration of treatment

• GORD-specific risk: sleeve gastrectomy may cause new or worsened reflux, occasionally requiring conversion to gastric bypass

Post-operatively, patients should expect a structured recovery period with a staged return to eating, beginning with fluids and progressing to soft and then solid foods over several weeks. Lifelong micronutrient supplementation and annual biochemical monitoring are essential after bariatric surgery and should follow the recommendations of the British Obesity and Metabolic Surgery Society (BOMSS). Patients who have undergone bariatric surgery and have a history of Barrett's oesophagus or significant oesophagitis should continue oesophageal surveillance in line with British Society of Gastroenterology (BSG) guidance, and should report any persistent or new reflux symptoms to their surgical team.

If you are taking PPIs or other medicines and experience unexpected symptoms that may be related to your medication, you can report these to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Talking to Your GP or Specialist About Your Options

Patients with obesity and poorly controlled GORD should speak to their GP about NICE eligibility and referral, keeping a symptom diary and seeking urgent review if alarm symptoms such as dysphagia or unintentional weight loss develop.

If you are living with obesity and experiencing persistent GORD symptoms that are not adequately controlled with lifestyle changes or medication, it is worth having an open conversation with your GP about whether bariatric surgery might be appropriate for you. Your GP can review your current treatment, assess your eligibility based on NICE criteria (CG189), and initiate a referral to a specialist weight management service if indicated.

When preparing for this conversation, it may be helpful to:

• Keep a symptom diary noting the frequency and severity of heartburn, regurgitation, or other GORD symptoms

• Record your current medications, including any PPIs or antacids you are taking

• Note any previous investigations, such as endoscopy results or pH monitoring studies

• Be honest about your weight history and any previous attempts at weight management

It is also important to have realistic expectations. Bariatric surgery is not a quick fix, and its success depends on sustained lifestyle changes, lifelong nutritional monitoring, and ongoing engagement with healthcare professionals. For patients with GORD, the choice of procedure is particularly significant, and a specialist bariatric MDT — comprising surgeons, dietitians, psychologists, and physicians — will work with you to identify the most appropriate option.

You should seek urgent medical attention — by contacting your GP, calling NHS 111, or attending an emergency department — if you experience any of the following alarm symptoms, which may indicate serious oesophageal or gastric pathology requiring prompt investigation:

• Difficulty swallowing (dysphagia) at any age

• Unintentional weight loss

• Persistent vomiting

• Vomiting blood or material that looks like coffee grounds

• Black, tarry, or dark red stools

• Iron-deficiency anaemia

• Upper abdominal pain that is new, persistent, or severe

These features align with the urgent referral criteria set out in NICE guidance NG12 (Suspected cancer: recognition and referral) and should not be ignored. Further information on GORD symptoms, management, and when to seek help is available on the NHS website.

Frequently Asked Questions